These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21143511)

  • 21. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
    Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
    Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.
    Zonios D; Yamazaki H; Murayama N; Natarajan V; Palmore T; Childs R; Skinner J; Bennett JE
    J Infect Dis; 2014 Jun; 209(12):1941-8. PubMed ID: 24403552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inherited long QT syndrome revealed by antifungals drug-drug interaction.
    Eiden C; Peyrière H; Tichit R; Cociglio M; Amedro P; Blayac JP; Margueritte G; Hillaire-Buys D
    J Clin Pharm Ther; 2007 Jun; 32(3):321-4. PubMed ID: 17489884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.
    Li-Wan-Po A; Girard T; Farndon P; Cooley C; Lithgow J
    Br J Clin Pharmacol; 2010 Mar; 69(3):222-30. PubMed ID: 20233192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance.
    Rosemary J; Adithan C
    Curr Clin Pharmacol; 2007 Jan; 2(1):93-109. PubMed ID: 18690857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene].
    Kimura M; Yamagishi Y; Kawasumi N; Hagihara M; Hasegawa T; Mikamo H
    Jpn J Antibiot; 2010 Jun; 63(3):255-64. PubMed ID: 20976881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics.
    Rengelshausen J; Banfield M; Riedel KD; Burhenne J; Weiss J; Thomsen T; Walter-Sack I; Haefeli WE; Mikus G
    Clin Pharmacol Ther; 2005 Jul; 78(1):25-33. PubMed ID: 16003289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
    Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
    Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes.
    Matsumoto K; Ikawa K; Abematsu K; Fukunaga N; Nishida K; Fukamizu T; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    Int J Antimicrob Agents; 2009 Jul; 34(1):91-4. PubMed ID: 19261446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
    Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
    J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.
    Hyland R; Jones BC; Smith DA
    Drug Metab Dispos; 2003 May; 31(5):540-7. PubMed ID: 12695341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency.
    Autmizguine J; Krajinovic M; Rousseau J; Théorêt Y; Litalien C; Marquis C; Tapiéro B; Ovetchkine P
    Pharmacogenomics; 2012 Dec; 13(16):1961-5. PubMed ID: 23215888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors affecting voriconazole plasma concentrations in patients with invasive fungal infections.
    Kim DY; Park HJ; Lee YJ
    Int J Clin Pharmacol Ther; 2014 Mar; 52(3):209-16. PubMed ID: 24424111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Voriconazole and fluconazole increase the exposure to oral diazepam.
    Saari TI; Laine K; Bertilsson L; Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 2007 Oct; 63(10):941-9. PubMed ID: 17676319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
    Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
    Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.
    Andrews E; Damle BD; Fang A; Foster G; Crownover P; LaBadie R; Glue P
    Br J Clin Pharmacol; 2008 Apr; 65(4):531-9. PubMed ID: 18294327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of cytochrome P450 gene polymorphism in a lupus nephritis patient in whom tacrolimus blood concentration was markedly elevated after administration of azole antifungal agents.
    Fujita Y; Araki T; Okada Y; Aomori T; Shimizu R; Tomizawa T; Hiromura K; Nojima Y; Nakamura T; Yamamoto K
    J Clin Pharm Ther; 2013 Feb; 38(1):74-6. PubMed ID: 22971159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerated metabolism of voriconazole and its partial reversal by cimetidine.
    Moriyama B; Elinoff J; Danner RL; Gea-Banacloche J; Pennick G; Rinaldi MG; Walsh TJ
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1712-4. PubMed ID: 19171800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcriptional regulation of CYP2C19 and its role in altered enzyme activity.
    Uppugunduri CR; Daali Y; Desmeules J; Dayer P; Krajinovic M; Ansari M
    Curr Drug Metab; 2012 Oct; 13(8):1196-204. PubMed ID: 22804232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole.
    Grün B; Krautter S; Riedel KD; Mikus G
    Br J Clin Pharmacol; 2009 Nov; 68(5):712-20. PubMed ID: 19916995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.